SEC Comment Letter for RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636) — Nov 2, 2020
RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636)
Date: Nov. 2, 2020 · CIK: 0000849636 · Accession: 0000000000-20-010359
AI Filing Summary & Sentiment
File numbers found in text: 001-16467
Letter
United States securities and exchange commission logo November 2, 2020 Timothy Jones President and Chief Executive Officer RespireRx Pharmaceuticals Inc. 126 Valley Road, Suite C Glen Rock, NJ 07452 Re:RespireRx Pharmaceuticals Inc. Preliminary Proxy Statement on Schedule 14A Filed October 20, 2020 File No. 001-16467 Dear Mr. Jones: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Elizabeth A. Diffley, Esq.
Show Raw Text
United States securities and exchange commission logo
November 2, 2020
Timothy Jones
President and Chief Executive Officer
RespireRx Pharmaceuticals Inc.
126 Valley Road, Suite C
Glen Rock, NJ 07452
Re:RespireRx Pharmaceuticals Inc.
Preliminary Proxy Statement on Schedule 14A
Filed October 20, 2020
File No. 001-16467
Dear Mr. Jones:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Elizabeth A. Diffley, Esq.